Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo

Gene Therapy

Volumn 4, Issue 4, 1997, Pages 309-316

  Kuzmin, A I ^a   Finegold, M J ^a   Eisensmith, R C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Gene therapy; Immunomodulation; Macrophage depletion

Indexed keywords

ALPHA 1 ANTITRYPSIN; CLODRONIC ACID; LIPOSOME;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT GENE; SURVIVAL RATE;

EID: 0030943732     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300377     Document Type: Article

References (37)

1. Kozarsky K, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499-503.
2. Kay MA, Woo SLC. Gene therapy for metabolic disorders. Trends Genet 1994; 10: 253-257.
3. Haddada H, Cordier L, Perricaudet M. Gene therapy using adenovirus vectors. Curr Top Microbiol Immunol 1995; 199: 297-306.
4. Englehardt JF, Litzky L, Wilson JM. Prolonged transgene expression in Cotton rat lung with recombmant adenoviruses defective in E2a. Hum Gene Ther 1994; 5: 1217-1229.
5. Englehardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
6. Yang Y, Ertl HCJ, Wilson JM. MHC class I-resrricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
7. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
8. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
9. Fang B et al. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Therapy 1994; 1: 247-254.
10. Fang B et al. Gene therapy for hemophilia B: host immuno-suppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
11. Zsengeller ZK et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
12. Seljelid R, Eskeland T. The biology of macrophages: I General principles and properties. Eur J Haematol 1993; 51: 267-275.
13. Delemarre FG, Kors N, van Rooijen N. Elimination of spleen and Iymph node macrophages and its difference in the effect on the immune response to particulate antigens. Immunology 1990; 182: 70-78.
14. van Rooijen N. Antigen processing and presentation in vivo: the microenvironment as a crucial factor. Immunol Today 1990; 11: 436-439.
15. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother 1994; 48: 445-453.
16. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-179.
17. Gordon S, Clarke S, Greaves D, Doyle A. Molecular immunobiology of macrophages: recent progress. Curr Opin Immunol 1995; 7: 24-33.
18. van Rooijen N. Macrophages as accessory cells in the in vivo humoral response: from processing of particulate antigens to regulation by suppression. Semin Immunol 1992; 4: 237-245.
19. Gajewski TF, Pinnas M, Wong T. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol 1991; 146: 1750-1758.
20. Brewer JM, Richmond J, Alexander J. The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies. Clin Exp Immunol 1994; 97: 164-171.
21. Nair S et al. The role of macrophages and dendritic cells in primary T lymphocyte responses. Int Immunol 1995; 7: 679-688.
22. Barr D et al. Strain-related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
23. van Rooijen N, Sanders A. Liposome-mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Meth 1994; 174: 83-93.
24. - recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and dogs. Gene Therapy 1996; 3: 217-222.
25. Moonis M, Ahmad I, Bachhawat BM. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B. J Antimicrob Chemother 1994; 33: 571-583.
26. Stapleton JT. Host immune response to hepatitis A virus- J Infect Dis Suppl 1995; 171 (Suppl.): S9-S14.
27. Arankalle VA et al. Cross-challenge studies in rhesus monkeys employing different Indian isolate of hepatitis E virus, J Med Virol 1995; 46: 358-363.
28. Rubin DH, Eaton MA, Costello T. Reovirus type 1 is secreted into the bile. J Virol 1986; 60: 726-728.
29. Bojang K, Walters MD. Toxic shock-like syndrome caused by adenovirus infection. Arch Dis Child 1992; 67: 1112-1114.
30. Day DB, Zachariades NA, Gooding LR. Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. Cell Immunol 1994; 157: 233-238.
31. Gooding LR. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis 1994; 3: 106-115.
32. Kolls JK et al. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995; 171: 570-575.
33. Salkowski CA et al. Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radio-protection. J Immunol 1995; 155: 3168-3179.
34. van Ginkel FW et al. Th1 and Th2 mediated immune responses in the respiratory tract following intranasal immunization with replication-deficient adenoviral vectors. FASEB J 1996; 10: A1190.
35. Kay MA, Graham F, Leland F, Woo SLC. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995; 21: 815-819.
36. Halbert DM, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250-257.
37. Graham FL, Prevec L. Manipulation of adenovirus vector. In: Murray EJ (ed). Methods in Molecular Biology: Gene Transfer and Expression Protocols, Vol 7. The Humana Press: Clifton, NJ, 1991, pp 109-128.